title: [Phosphate kinetics in patients on chronic hemodialysis].
abstract: To investigate the phosphate kinetics in hemodialysis (HD), 8 patients in a stable condition, who were receiving HD three times a week for 4 hours per session, were investigated. Plasma phosphate was under 7 mg/dl, and residual renal function had almost disappeared. Dialysate containing phosphate was prepared by adding Na2HPO4 using a micro-infusion pump from the inlet of single pass dialysate in the individual dialysate delivery system. In the first week, Na2HPO4 was not added as the control period. In the second session of the second and third week, Na2HPO4 was added to give a phosphate concentration of 1.0 and 2.0 mmol/l in the dialysate, respectively. Total phosphate mass removal was 777 +/- 46.64 mg in the control period, 403 +/- 67.21 mg in the second week, and -230 +/- 214.8 mg in the third week. Total phosphate mass removal in the second and third week was significantly lower than that of the control period. Plasma phosphate concentration was significantly decreased after the HD compared with before the HD in the control and second week. There was no significant difference in plasma phosphate concentration between the period before HD and at 48 hours in the control and the second week. Plasma phosphate concentration before HD not only depended on phosphate mass removal by HD, but also on other factors. We suggest that dialysate containing phosphate might prevent excessive phosphate removal from non-extracellular compartments during HD.
authors.affiliation: Second Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Okuda
authors.forename: T
authors.initials: T
authors.lastname: Kuno
authors.forename: Y
authors.initials: Y
authors.lastname: Nagura
authors.forename: K
authors.initials: K
authors.lastname: Kanmatsuse
mesh_terms: D000328:Adult; D015314:Dialysis Solutions; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000008:administration & dosage / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D015314:Dialysis Solutions; D010710:Phosphates